Clinical study on the new adjuvant chemotherapy for the treatment of osteosarcoma
LIN Feng,TANG Xiao-chun,CAI Xun,YAO Yang (Department of Oncology,Shanghai Jiaotong University Affiliated Sixth People's Hospital,Shanghai 200233,China)
Aim To evaluate the clinical and side effects of the new adjuvant chemotherapy for the treatment of osteosarcoma.Methods 35 cases were divided into the new adjuvant chemotherapy and adjuvant chemotherapy groups. 20 cases in the new adjuvant chemotherapy group were treated with preoperative ultra-high dose chemotherapy for one or two periods,and postoperative chemotherapy for 4～6 courses.Postoperative chemotherapy regimen was adjusted according to the tumor necrosis rate.15 cases in another group were treated only with postoperative chemotherapy for 4~6 courses. The clinical and adverse effect of these two groups were evaluated.Results In the group of new adjuvant chemotherapy,the tumor necrosis rate was over 90% in 14 cases,under 90% in 6 cases.2-year metastasis rate and 2-year survival rate after surgery were 25.0% and 80.0%,respectively.And the clinical effect was better than that in the adjuvant group.The main adverse effects in the chemotherapy were myelosuppression,gastriotestinal reaction,the damage of liver and renal function.ConclusionThe new adjuvant chemotherapy can decrease the metastsis rate and increase the survival rate in osteosarcoma patients,and it is an ideal therapy for osteosarcoma.
【CateGory Index】： R738.1